Qiagen N.V.

  • WKN: A2DKCH
  • ISIN: NL0012169213
  • Land: The Netherlands

Nachricht vom 08.10.2021 | 22:04

QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

QIAGEN N.V.
08.10.2021 / 22:04
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The AFM (the Netherlands Authority For the Financial Markets) has informed us on October 5, 2021 that a notification related to our institution has been released by the AFM.

The following notification has been disclosed in the relevant register on the AFM website:

Date of transaction: 01 oct 2021
Person obliged to notify: BlackRock, Inc.
Issuing institution: Qiagen N.V.
Registration Chamber of Commerce: 12036979
Place of residence: VENLO

Distribution in numbers

Type of share Number of shares Number of voting rights Capital interest Voting rights Manner of disposal Settlement
Ordinary share 32.266.732,00 34.614.604,00 Real Real Indirectly - BlackRock, Inc.  
Contract for difference 117.211,00 117.211,00 Potential Potential Indirectly - BlackRock, Inc. In Cash
Ordinary share 814.466,00 814.466,00 Potential Potential Indirectly - BlackRock, Inc. Physical Delivery
 


Distribution in percentages

Type Total holding Directly real Directly potential Indirectly real Indirectly potential
Capital interest 14,38 % 0,00 % 0,00 % 13,98 % 0,40 %
Voting rights 15,40 % 0,00 % 0,00 % 15,00 % 0,40 %
 

QIAGEN N.V. is not responsible for the accuracy and correctness of the notification above. The content has been taken from the relevant register of the AFM:
https://www.afm.nl/en/professionals/registers/meldingenregisters/substantiele-deelnemingen/details?id=116131



08.10.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021